EUVIMEDEUVIMED entdecken
Open Access

[ 177 Lu]Lu-DOTATATE Population Pharmacokinetics and Dosimetry Modeling for Adolescent and Adult Patients with Somatostatin ReceptorPositive Gastroenteropancreatic Neuroendocrine Tumors

Meemansa Sood, Larissa Lachi Silva, Yu-Yun Ho, Lars Blumenstein, Azzeddine Cherfi, Lingfei Xu, Fariba Khanshan

Journal of Nuclear Medicine · 2026

DOI: 10.2967/jnumed.125.270202 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Nuclear Medicine, 2026. Verfasst von Meemansa Sood und 6 weiteren Autor:innen. Beteiligte Einrichtung: Novartis Pharma AG, Basel, Switzerland. Hauptthemen laut MEDLINE: Neuroendocrine Tumors, Octreotide, Organometallic Compounds, Pancreatic Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

There is an unmet need for treatment options for adolescents with malignant advanced gastroenteropancreatic neuroendocrine tumors or pheochromocytomas and paragangliomas. Whether radiopharmaceutical therapy dosing strategies for adults are suitable for adolescents is unknown. This study compared the plasma exposure and cumulative absorbed radiation dose of [177Lu]Lu-DOTATATE (177Lu-DOTATATE) between adults and adolescents treated with 7.4 GBq for 4 cycles every 8 wk to assess the probability of adolescent doses exceeding predefined safety thresholds for kidney and bone marrow dosimetry.

Methods

Population pharmacokinetics (popPK) and exposure-dosimetry models for 177Lu-DOTATATE, developed for adults, and simulations based on the exposure-dosimetry model, were used to determine sample size for the NETTER-P trial, assuming that the same dosage is administered to adolescents as to adults. Subsequently, a popPK model on adolescents and an exposure-dosimetry model on pooled adult and adolescent data were developed, and the results were compared with those from adult models.

Results

PopPK models for adults and adolescents showed no significant covariate effects. Applying an adult dosimetry model to an adolescent population predicted median kidney and bone marrow dosimetry values below predefined safety threshold levels of 29 Gy or less and 2 Gy or less, respectively. PopPK modeling confirmed comparable 177Lu-DOTATATE exposure, and kidney and bone marrow dosimetry values were predicted to be largely below threshold levels. The observed proportions and median predicted probabilities of exceeding thresholds after 4 cycles were approximately 20% for kidney or significantly below 20% for bone marrow, which was considered an acceptable safety limit. Age and weight did not show a clinically significant impact on 177Lu-DOTATATE exposure or kidney and bone marrow dosimetry values, confirming that flat dosing at adult dosage is appropriate for adolescents.

Conclusion

177Lu-DOTATATE with 7.4 GBq of activity, administered over 4 cycles 8 wk apart, is a well-tolerated therapeutic dosing regimen for adolescent patients with gastroenteropancreatic neuroendocrine tumors or pheochromocytomas and paragangliomas.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neuroendocrine TumorsOctreotideOrganometallic CompoundsPancreatic NeoplasmsModels, BiologicalReceptors, SomatostatinStomach NeoplasmsIntestinal NeoplasmsHumansAdolescentAdultRadiometryFemaleMaleYoung AdultMiddle AgedRadiopharmaceuticalsAged

Stichwörter der Autor:innen

177Lu-DOTATATERLTRPTadolescent dosage extrapolationexposure–dosimetry modelingpopulation pharmacokinetics modelingradioligand therapyradiopharmaceutical therapy

Substanzen

OctreotideOrganometallic Compoundslutetium Lu 177 dotatateReceptors, SomatostatinRadiopharmaceuticals

Autor:innen und Institutionen

  • Novartis Pharma AG, Basel, Switzerland.
  • Novartis Pharmaceuticals Corporation, East Hanover, New Jersey; larissa.lachi_silva@novartis.com.
  • Novartis Pharmaceuticals Corporation, East Hanover, New Jersey.
  • Novartis Institutes for BioMedical Research, Basel, Switzerland; and.
  • Novartis Pharmaceuticals Corporation, Cambridge, Massachusetts.

Zitieren

APA

Sood, M., Lachi Silva, L., Ho, Y. Y., Blumenstein, L., Cherfi, A., Xu, L., & Khanshan, F. (2026). [ 177 Lu]Lu-DOTATATE Population Pharmacokinetics and Dosimetry Modeling for Adolescent and Adult Patients with Somatostatin ReceptorPositive Gastroenteropancreatic Neuroendocrine Tumors. Journal of Nuclear Medicine. https://doi.org/10.2967/jnumed.125.270202

Vancouver

Sood M, Lachi Silva L, Ho YY, Blumenstein L, Cherfi A, Xu L, et al. [ 177 Lu]Lu-DOTATATE Population Pharmacokinetics and Dosimetry Modeling for Adolescent and Adult Patients with Somatostatin ReceptorPositive Gastroenteropancreatic Neuroendocrine Tumors. Journal of Nuclear Medicine. 2026. doi:10.2967/jnumed.125.270202

BibTeX
@article{Sood2026,
  author = {Sood, Meemansa and Lachi Silva, Larissa and Ho, Yu-Yun and Blumenstein, Lars and Cherfi, Azzeddine and Xu, Lingfei and Khanshan, Fariba},
  title = {[ 177 Lu]Lu-DOTATATE Population Pharmacokinetics and Dosimetry Modeling for Adolescent and Adult Patients with Somatostatin ReceptorPositive Gastroenteropancreatic Neuroendocrine Tumors},
  journal = {Journal of Nuclear Medicine},
  year = {2026},
  doi = {10.2967/jnumed.125.270202}
}
Kostenlos starten →